Clinical Trials

140 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

270 enrolled

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03587311 2026-04-13

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

96 enrolled

Fallopian Tube Endometrioid Adenocarcinoma

NCT03694262 2026-04-13

EndoBARR

30 enrolled 7 charts

Endometrial Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT07504588 2026-04-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07024784 2026-04-06

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

377 enrolled

Fallopian Tube Neoplasms, Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07497074 2026-03-27

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

78 enrolled

Uterine Cervical Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT02884648 2026-02-06

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

35 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07370818 2026-01-27

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

81 enrolled

Ovarian Neoplasms

NCT07054567 2026-01-21

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

96 enrolled

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT07314619 2026-01-02

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

30 enrolled

Platinum-resistant Recurrent Ovarian Cancer (PROC)

NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

38 enrolled

Ovarian Neoplasms

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

17 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07059845 2025-12-04

FLORENZA

320 enrolled

Ovarian Neoplasms

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT03526432 2025-10-24

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

110 enrolled

Endometrial Neoplasms

NCT05446870 2025-10-01

MK-4830-002

160 enrolled 19 charts

Ovarian Neoplasms

NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

33 enrolled

Ovarian Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

37 enrolled

Advanced Ovarian Cancer

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

77 enrolled 8 charts

Ovarian Neoplasms

NCT06540729 2025-07-08

DAB

39 enrolled

Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT05044871 2025-06-08

BRIGHT

108 enrolled

Ovarian Neoplasms

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

38 enrolled 12 charts

Endometrial Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

7 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT04868708 2025-03-04

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

50 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Uterine Cervical Neoplasms, Recurrence

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04175470 2025-01-03

Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

20 enrolled

Ovarian Cancer Recurrent

NCT06735326 2024-12-16

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

105 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Ovarian Neoplasms

NCT04787289 2024-08-07

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

244 enrolled

Ovarian Neoplasms

NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

39 enrolled

Platinum-resistant Recurrent Ovarian Cancer

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

22 enrolled

Platinum-sensitive Relapsed Ovarian Cancer

NCT03093155 2024-05-14

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

78 enrolled 18 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

9 enrolled 9 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03476798 2024-02-15

Clovis-001

49 enrolled 13 charts